Evidence map›Paper›PMID 39474429›Full record

ArticleFrontiers in immunology2024

Making the effect visible - OX40 targeting nanobodies for

Desiree I Frecot, Simone Blaess, Teresa R Wagner, Philipp D Kaiser, Bjoern Traenkle, Madeleine Fandrich, Meike Jakobi, Armin M Scholz, Stefan Nueske, Nicole Schneiderhan-Marra and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Desiree I FrecotPharmaceutical Biotechnology, University Tübingen, Tübingen, Germany.
Simone BlaessNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Teresa R WagnerNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Philipp D KaiserNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Bjoern TraenkleNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Madeleine FandrichNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Meike JakobiNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Armin M ScholzLivestock Center of the Faculty of Veterinary Medicine, Ludwig Maximilians University Munich, Oberschleissheim, Germany.
Stefan NueskeLivestock Center of the Faculty of Veterinary Medicine, Ludwig Maximilians University Munich, Oberschleissheim, Germany.
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Cécile GouttefangeasCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Manfred KneillingCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Bernd J PichlerCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Dominik SonaniniCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Ulrich RothbauerPharmaceutical Biotechnology, University Tübingen, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Human OX40 (hOX40/CD134), a member of the TNF receptor superfamily, is mainly expressed on activated T lymphocytes. Triggered by its ligand OX40L (CD252), it provides costimulatory signals that support the differentiation, proliferation and long-term survival of T cells. Besides being a relevant therapeutic target, hOX40 is also an important biomarker for monitoring the presence or infiltration of activated T cells within the tumor microenvironment (TME), the inflammatory microenvironment (IME) in immune-mediated diseases (IMIDs) and the lymphatic organs. Here, we developed novel single domain antibodies (nanobodies, Nbs) targeting hOX40 to monitor the activation status of T cells by Methods: Nbs against hOX40 (hOX40-Nbs) were selected from an immunized Nb-library by phage display. The identified hOX40-Nbs were characterized Results: Our selection campaign revealed four unique Nbs that exhibit strong binding affinities and high stabilities under physiological conditions. Epitope binning and domain mapping indicated the targeting of at least two different epitopes on hOX40. When analyzing their impact on OX40 signaling, an agonistic effect was excluded for all validated Nbs. Incubation of activated T cells with hOX40-Nbs did not affect cell viability or proliferation patterns, whereas differences in cytokine release were observed. Conclusion: Considering the need for advanced probes for noninvasive

Indexed as

Lymphocyte ActivationReceptors, OX40Single-Domain AntibodiesT-LymphocytesAnimalsCell Line, TumorHumansMiceMolecular ImagingOptical ImagingTumor MicroenvironmentReceptors, OX40Single-Domain AntibodiesTNFRSF4 protein, humanin vivo imagingmonitoring immunotherapiesnanobodyOX40T cell activationtumor microenvironment (TME)

Identifiers

PMID39474429
PMCPMC11518761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.